-
11.发明公开公开(公告)号：US20240083969A1
公开(公告)日：2024-03-14
申请号：US18321820
申请日：2023-05-23
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH , Gisela SCHIMMACK , Michael ROEMER
IPC: C07K14/725 , A61K9/19 , A61K35/17 , A61K39/00 , A61P35/00 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/115 , G01N33/574 , G16B25/10
CPC classification number: C07K14/7051 , A61K9/19 , A61K35/17 , A61K39/001111 , A61P35/00 , C07K14/70539 , C07K16/2809 , C07K16/2833 , C12N5/0638 , C12N15/115 , G01N33/57492 , G16B25/10 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20240067697A1
公开(公告)日：2024-02-29
申请号：US18489600
申请日：2023-10-18
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Lena WULLKOPF , Christoph SCHRAEDER , Jens FRITSCHE , Daniel Johannes KOWALEWSKI , Michael ROEMER , Oliver SCHOOR
IPC: C07K14/725 , A61K35/17 , C07K14/74 , C07K16/28
CPC classification number: C07K14/7051 , A61K35/17 , C07K14/70539 , C07K16/2833 , A61K38/00
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO:1 to SEQ ID NO:113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
13.发明公开公开(公告)号：US20240016913A1
公开(公告)日：2024-01-18
申请号：US18458233
申请日：2023-08-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Ricarda HANNEN , Christoph SCHRAEDER , Jens FRITSCHE , Franziska HOFFGAARD , Daniel Johannes KOWALEWSKI , Oliver SCHOOR
IPC: A61K39/00 , A61P35/00 , C07K14/705 , C07K14/74
CPC classification number: A61K39/0011 , A61P35/00 , C07K14/705 , C07K14/70539 , A61K39/00 , A61K2039/5158
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
14.发明公开公开(公告)号：US20240016910A1
公开(公告)日：2024-01-18
申请号：US18455683
申请日：2023-08-25
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Ricarda HANNEN , Christoph SCHRAEDER , Jens FRITSCHE , Franziska HOFFGAARD , Daniel Johannes KOWALEWSKI , Oliver SCHOOR
IPC: A61K39/00 , A61P35/00 , C07K14/705 , C07K14/74
CPC classification number: A61K39/0011 , A61P35/00 , C07K14/705 , C07K14/70539 , A61K39/00 , A61K2039/5158
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
15.发明公开公开(公告)号：US20230285460A1
公开(公告)日：2023-09-14
申请号：US18162380
申请日：2023-01-31
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61K39/00 , A61K45/06 , C07K16/28 , C07K7/06 , C07K16/24 , C12N5/0783 , A61P35/02 , A61K39/39 , A61K39/395 , A61K38/08 , C07K14/54 , A61K39/12 , C07K14/47 , A61P35/00 , A61K45/00
CPC classification number: A61K35/17 , A61K39/001102 , A61K39/001118 , A61K39/001114 , A61K45/06 , C07K16/2818 , C07K7/06 , C07K16/244 , C12N5/0636 , A61P35/02 , A61K39/39 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/5434 , A61K39/12 , C07K14/4748 , A61P35/00 , A61K2039/55538 , A61K45/05 , A61K2039/55533 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , A61K2039/5154 , A61K2039/55561 , A61K2039/55516 , A61K2039/5156
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
公开(公告)号：US20230227518A1
公开(公告)日：2023-07-20
申请号：US18161423
申请日：2023-01-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Franziska HOFFGAARD , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61K39/00 , C07K16/30 , C12N5/0783 , C07K14/725 , A61K45/06 , A61K35/17 , C12N15/115 , A61P35/02 , A61P35/00 , C07K14/74 , C07K16/28
CPC classification number: C07K14/4748 , A61K39/0011 , C07K16/3053 , C07K16/30 , C07K16/3015 , C07K16/3023 , C12N5/0636 , C07K14/7051 , C07K16/303 , A61K39/001193 , A61K45/06 , A61K35/17 , C07K16/3069 , C12N15/115 , C07K16/3046 , A61P35/02 , A61K39/001186 , C07K16/3038 , C07K16/3061 , A61P35/00 , C07K14/70539 , C07K16/2833 , C07K2319/00 , C12N2310/16
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
17.发明公开公开(公告)号：US20230227517A1
公开(公告)日：2023-07-20
申请号：US18158734
申请日：2023-01-24
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni WEINSCHENK , Helen HOERZER , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/47 , A61K35/17 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/705 , C07K14/74 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/32 , C12N5/0783 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/569 , G01N33/574
CPC classification number: C07K14/4748 , A61K35/17 , A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/4705 , C07K14/4738 , C07K14/705 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K16/32 , C12N5/0636 , C12N15/115 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , G01N33/56977 , G01N33/57449 , G01N33/57492 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20230203114A1
公开(公告)日：2023-06-29
申请号：US18063430
申请日：2022-12-08
Applicant: Immatics Biotechnologies GmbH
Inventor： Oliver SCHOOR , Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/47 , A61P35/00 , A61K39/00 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/113 , C07K14/725 , C07K16/30
CPC classification number: C07K14/4748 , A61P35/00 , A61K39/001154 , A61K39/0011 , C07K14/70539 , C07K16/2833 , C12N5/0636 , C12N15/1138 , C07K14/7051 , C07K16/3046 , C07K16/3076 , C07K2317/34 , C12N2501/50 , C12N2310/16 , A61K2039/5154 , A61K2039/5158
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
19.发明公开公开(公告)号：US20230192791A1
公开(公告)日：2023-06-22
申请号：US17934663
申请日：2022-09-23
Applicant: Immatics Biotechnologies GmbH
Inventor： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , C07K16/28 , C12N15/115 , G01N33/574 , C07K14/54 , C07K7/06 , C12N5/0783 , C07K16/30 , A61K39/00 , C07K14/74 , A61P35/00 , C07K14/725 , C12N15/10 , A61K35/17
CPC classification number: C07K14/4748 , C07K16/2818 , C12N15/115 , G01N33/57492 , C07K14/5434 , C07K7/06 , C12N5/0638 , C07K16/30 , A61K39/0011 , C07K14/70539 , A61P35/00 , A61K39/001102 , C07K14/7051 , C12N15/1062 , A61K35/17 , A61K2039/572 , C07K2319/00 , A61K2039/5158 , C12N2501/50 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20230190808A1
公开(公告)日：2023-06-22
申请号：US17938577
申请日：2022-10-06
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Jens FRITSCHE , Oliver SCHOOR , Frank SCHWOEBEL , Lena Katharina FREUDENMANN
IPC: A61K35/17 , C07K14/725 , C12N5/0783 , C12N5/10
CPC classification number: A61K35/17 , C07K14/7051 , C12N5/0638 , C12N5/10
Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
-
-
-
-
-
-
-
-
-
Search Results
645
records
(took 0.021 seconds)
